drugset / Trial / NCT00878904
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors
Phase 1
Completed
40 enrolled
University of California, San Francisco
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as epirubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving panobinostat together with epirubicin may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of panobinostat when given together with epirubicin in treating patients with metastatic malignant solid tumors.
Timeline
- Start
- 2009-09-13
- Primary completion
- 2013-05
- Completion
- 2016-10-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epirubicin | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Panobinostat | Small molecule | 20 mg | Oral |
| Subject | Panobinostat | Small molecule | 50 mg | Oral |
| Subject | Panobinostat | Small molecule | 60 mg | Oral |